Vapendavir
- Generic Name
- Vapendavir
Vapendavir Shows Promise in Phase 2 Trial for Rhinovirus-Induced COPD Exacerbations
• Altesa BioSciences' oral antiviral vapendavir demonstrated positive results in a Phase 2 placebo-controlled rhinovirus challenge study, improving both upper and lower respiratory symptoms in COPD patients.
• The FDA recently cleared Altesa's Investigational New Drug application for vapendavir to treat rhinovirus infections in COPD patients, allowing the company to expand clinical trials from the UK to the United States.
• Vapendavir works by preventing rhinovirus from entering cells and reproducing, showing activity against 97% of tested rhinoviruses, potentially addressing a major cause of COPD exacerbations affecting over 16.4 million Americans.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath